10-K: SANUWAVE Health, Inc. Reports 22% Revenue Growth in 2023, Eyes Merger Completion

SANUWAVE Health, Inc. saw a 22% increase in revenue in 2023 and is working towards completing a merger with SEP Acquisition Corp.

Summary

• SANUWAVE Health, Inc. experienced a 22% revenue increase in 2023, reaching $20.4 million, compared to $16.7 million in 2022.
• Gross margins decreased slightly to 70% in 2023 from 74% in 2022.
• The company significantly reduced its operating loss by 94% to $0.5 million for the year ended December 31, 2023.
• Net loss for 2023 was $25.8 million, or ($0.03) per share, compared to a net loss of $10.3 million, or ($0.02) per share, in 2022, with the variance largely due to a non-cash change in the fair value of derivatives.
• The company is in default under several promissory notes and is working to regain compliance.
• A merger agreement with SEP Acquisition Corp. was approved by stockholders in February 2024, with a potential closing date extended to April 30, 2024.
• The company is focused on commercializing its UltraMIST and PACE systems for wound healing and regenerative medicine.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is positive revenue growth and a reduction in operating losses, the significant net loss, defaults on debt, and material weaknesses in internal controls raise concerns. The company's future is heavily reliant on the successful completion of the merger and securing additional capital.

Positives

• The company achieved a 22% increase in revenue in 2023.
• Operating loss was significantly reduced by 94% in 2023.
• The company has secured commitments from holders of approximately 95% of outstanding warrants and 100% of outstanding convertible notes to exchange them for common stock prior to the merger.
• The merger agreement with SEPA was approved by a majority vote of the company's common stockholders.
• The company is focused on commercializing its patented, non-invasive medical systems for regenerative medicine.

Negatives

• The company experienced a net loss of $25.8 million in 2023.
• Gross margins decreased from 74% in 2022 to 70% in 2023.
• The company is currently in default under several promissory notes.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company's ability to continue as a going concern is dependent on raising additional capital.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company is in default under several promissory notes, which could lead to acceleration of debt payments.
• The merger with SEPA is subject to conditions, including a minimum cash condition, that may not be satisfied.
• The company faces intense competition in the medical device industry.
• The company is subject to extensive governmental regulation, including FDA approval requirements.
• The company faces risks related to cybersecurity breaches and data leakage.
• The company's stock price is volatile and may be affected by various factors.

Future Outlook

The company plans to obtain additional capital in 2024, primarily through the completion of the merger agreement with SEPA. The company also plans to continue commercializing its UltraMIST and PACE systems and develop new applications for its technology.

Management Comments

• Management plans to obtain additional capital in 2024 through the completion of the Merger Agreement.
• Management believes that potential additional issuances of equity or other potential financing transactions should provide the necessary funding for the company over the next 12 months.

Industry Context

The company operates in the competitive medical device industry, facing competition from established companies and new technologies. The company's focus on non-invasive, biological response-activating medical systems positions it within the growing regenerative medicine market. The company's products compete with traditional wound care methods and other advanced therapies.

Comparison to Industry Standards

• The company's 22% revenue growth is a positive sign, but its net loss and negative EBITDA indicate that it is still in a growth phase and not yet profitable.
• The company's gross margin of 70% is within the range of other medical device companies, but there is room for improvement.
• The company's operating loss reduction is a positive trend, but it needs to continue to reduce costs and improve efficiency.
• The company's reliance on debt financing and the defaults on its promissory notes are a concern, and it needs to secure additional capital to continue operations.
• The company's merger with SEPA is a significant event that could provide it with the capital and resources it needs to grow and compete effectively.

Management Changes

Legal Proceedings

• The company is involved in various legal proceedings in the ordinary course of business, but does not believe any will have a material adverse effect.
• The company received notification alleging non-compliance with a license agreement with Celularity, but has responded and asserted that it is not in breach.

Related Party Transactions

• The company has entered into various transactions with related parties, including the issuance of convertible promissory notes and asset-backed secured promissory notes to directors and major stockholders.
• Certain directors and major stockholders have committed to exchange their outstanding warrants and convertible notes for shares of common stock immediately prior to the closing of the Business Combination.

Stakeholder Impact

• Shareholders face the risk of dilution from potential equity issuances and the uncertainty of the merger.
• Employees may experience uncertainty due to the ongoing financial challenges and the pending merger.
• Customers may be affected by any disruptions in the company's operations or product availability.
• Creditors face the risk of non-payment due to the company's defaults on its promissory notes.

Next Steps

• The company will focus on completing the merger with SEP Acquisition Corp.
• The company will work to remediate the material weaknesses in its internal control over financial reporting.
• The company will continue to commercialize its UltraMIST and PACE systems.
• The company will seek to develop new applications for its technology.

Key Dates

Keywords

regenerative medicine, wound healing, ultrasound, shock wave therapy, UltraMIST, PACE, merger, SEPA, medical devices, FDA approval, financial results, internal control, convertible notes, warrants